Vaccines / Preventive Services
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines. Visit our COVID-19 Intel Center to decipher the facts and plan for downstream business implications.
The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.
In 2020, the COVID-19 pandemic resulted in nationwide lockdowns and restrictions with a well-documented impact on utilization of routine healthcare services.
They bring more than 35 years of combined healthcare experience and expertise in the immunization development sector.
Immunization Information Systems (IIS), or immunization registries, are used across the US to provide consolidated and complete accounts of patient immunization history in a given city, state, or region.
As the pipeline of novel vaccines expands, so does the pipeline for other “vaccine-like” products.
Tune into another episode of Start Your Day with Avalere. In this segment, vaccines experts Richard Hughes IV and Dr. Angela Shen discuss the issue of vaccine hesitancy and the gaps in infrastructure and policy that affect adult vaccine uptake.
The proposed CY 2020 MPFS rule includes provisions that, if finalized, would increase provider reimbursement for vaccine administration. However, the proposed crosswalk of the codes to a separate, nonvaccine related code could subject the code to future unrelated payment fluctuations.
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss challenges within the vaccines marketplace and highlight the efforts currently underway to improve access and uptake among adults.
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.
Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.
Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.
A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.
Although influenza disease burden is high, vaccine uptake remains low.
An Avalere analysis finds that Medicare Part D plans allow $0 cost-sharing for select vaccines just 4% of the time, likely affecting immunization uptake.
On January 29, Richard Hughes published a piece on the Health Affairs blog discussing the presidential candidates’ opportunities to incorporate preventative services into their healthcare policy platforms.
On December 16, Avalere policy experts, including Senior Adviser Dr. Angela Shen, published a piece in Health Affairs blog entitled “Shaping the 2020 National Vaccine Plan.” It explores the progress to date against the 2010 National Vaccine Plan (NVP), recurring challenges, and the 2020 NVP.
Two decisions finalized in the CY 2020 Medicare Physician Fee Schedule (MPFS) rule have important implications for vaccine policy and access.
Since the 1980s, all 50 states have used immunization requirements as a condition of school entry to protect the public’s health from vaccine-preventable diseases.
On August 21, Avalere policy experts published a piece on the Health Affairs blog highlighting the impact of advancements in treatment and screening technology on the newborn screening landscape.
Dr. Angela Shen Joins the Firm